GLP-1 Drug Interactions: Oral Absorption, Insulin, and Common Medications

Written by Dan Cripe, RN, BSN & Marcia Cripe, RN | Last Updated: September 24, 2026

Starting a GLP-1 medication rarely means starting with an empty medication list. You may already take levothyroxine every morning, use insulin or a sulfonylurea for diabetes, rely on birth control pills, or reach for ibuprofen when your back or joints hurt.

So when you hear that GLP-1 medications can slow gastric emptying, lower blood glucose and dramatically change how much you eat, a very reasonable question follows: What happens to everything else I'm already taking?

For most medications, adding a GLP-1 does not create a dangerous direct drug-drug interaction. But there are several important exceptions and indirect interactions that are worth understanding because they can change how another medication is absorbed, how strongly it works or how safely it fits into your treatment.

Tirzepatide can temporarily affect the reliability of oral hormonal contraception. Combining GLP-1 therapy with insulin or medications that stimulate insulin secretion can increase the risk of hypoglycemia. Oral semaglutide has specific absorption issues with other oral medications, including documented effects on levothyroxine exposure, while significant vomiting, diarrhea or poor fluid intake can make medications such as NSAIDs more concerning for your kidneys.

That is the central idea that makes GLP-1 drug interactions easier to understand. The interaction is not always Drug A chemically conflicts with Drug B; sometimes the GLP-1 changes your physiology, and that changes the context in which Drug B is being taken.

Why GLP-1 Medications Can Affect Other Drugs

Medications can interact in several different ways. One drug may alter how another is metabolized by liver enzymes, increase or decrease another drug's blood concentration, or produce the same physiological effect so that the combined effect becomes excessive.

GLP-1 and related incretin medications are particularly relevant in two other ways: they can affect gastric emptying, and they can lower blood glucose. Both are therapeutic effects, but both can matter when another medication depends on predictable gastrointestinal absorption or also lowers glucose.

This is why memorizing a giant list of supposedly “safe” and “unsafe” combinations is less useful than understanding the mechanism. If you know that a medication depends on predictable oral absorption, affects glucose or becomes riskier during dehydration, you can begin to see why the interaction matters.

For you, the practical question is not simply whether two medications appear together on an interaction checker. It is whether your GLP-1 changes the physiology that the other medication depends on.

Delayed Gastric Emptying and Oral Contraceptive Failure Risks

If you are taking tirzepatide — Mounjaro or Zepbound — and you rely on an oral birth control pill, this is one interaction worth understanding before the first injection.

Tirzepatide delays gastric emptying, and that effect is generally greatest after the first dose before diminishing with repeated treatment. During periods when gastric emptying changes more substantially, the absorption of an oral medication can also change.

For oral hormonal contraceptives, that potential change matters enough that current tirzepatide labeling includes specific instructions. This is not simply a theoretical warning about delayed digestion; it is a labeled contraceptive recommendation tied specifically to tirzepatide.

What should you do with birth control pills when starting tirzepatide?

If you use an oral hormonal contraceptive, current Zepbound labeling advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting tirzepatide and four weeks after every dose increase.

That timing matters because tirzepatide is usually titrated. You may begin at 2.5 mg, increase several weeks later, and potentially increase again later in treatment, which means the backup-contraception recommendation can become relevant more than once.

This makes the warning much more important than a one-time sentence in the prescribing information. During the first several months of treatment, each dose escalation may create another period in which additional contraceptive protection is recommended.

If avoiding pregnancy is important to you, this is something to discuss with the clinician prescribing tirzepatide before treatment begins rather than after the first increase has already occurred.

Does tirzepatide make every form of birth control less effective?

No. The specific warning concerns oral hormonal contraceptives because those medications must be absorbed through the gastrointestinal tract.

Non-oral hormonal methods such as an IUD, implant, injection, vaginal ring or transdermal contraceptive do not depend on gastrointestinal absorption in the same way. They therefore represent a different pharmacologic situation from a pill moving through a stomach whose emptying may be delayed.

That distinction matters because the warning should not be expanded into the statement that “tirzepatide interferes with birth control” across the board. The route of contraception is part of the answer.

If you are starting tirzepatide, tell the prescriber exactly which contraceptive method you use so the recommendation can be matched to your actual situation.

Does Ozempic Interfere With Birth Control Pills Too?

This is where one medication-specific interaction should not be turned into a rule for the entire GLP-1 class.

Semaglutide also delays gastric emptying, but pharmacokinetic studies have not demonstrated the same clinically meaningful reduction in oral contraceptive exposure that led to the specific tirzepatide backup-contraception recommendation.

You therefore should not automatically apply the Mounjaro/Zepbound four-week backup rule to Ozempic or every GLP-1 medication. Drug-interaction advice should be matched to the specific medication rather than generalized from whichever product receives the most attention online.

There is still a practical issue that can affect any oral contraceptive, however. Significant vomiting or diarrhea can reduce the reliability of a birth control pill depending on when those symptoms occur relative to the dose.

If that happens, follow the missed-pill or vomiting instructions for your specific contraceptive and contact your pharmacist or prescriber if you are unsure. In that situation, the concern is not a unique semaglutide-drug interaction; it is whether the pill was adequately absorbed.

Managing Hypoglycemia: GLP-1s With Sulfonylureas or Insulin

GLP-1 receptor agonists are somewhat unusual among glucose-lowering medications because their insulin-stimulating effects are glucose dependent. They help increase insulin secretion when glucose is elevated rather than continuously forcing insulin release regardless of blood glucose.

That is one reason GLP-1 medications used alone generally have a relatively low risk of causing severe hypoglycemia. The situation changes when another glucose-lowering treatment is already part of your regimen.

If your GLP-1 improves glucose control while your food intake also falls substantially, an insulin or sulfonylurea regimen that previously matched your needs may no longer fit the same way. That is where the risk begins to increase.

Insulin changes the risk

Injected insulin continues lowering glucose according to its own pharmacologic action. It does not automatically adjust itself because your appetite suddenly dropped or because you ate half the amount you normally would.

Imagine starting a GLP-1 and finding that breakfast is suddenly difficult to finish. If your insulin regimen was built around your previous food intake while the GLP-1 is simultaneously improving your glucose control, the balance between insulin, food and blood glucose can shift.

That does not mean everyone using insulin must reduce it when starting a GLP-1. It means the regimen may need reassessment, especially if your glucose readings begin falling or your eating pattern changes significantly.

This is why your prescriber should know exactly which insulin you use, how much you take and how your glucose is behaving as GLP-1 treatment begins.

Sulfonylureas can do the same thing

Sulfonylureas such as glipizide, glimepiride and glyburide stimulate pancreatic insulin secretion. When they are combined with a GLP-1 medication, the likelihood of hypoglycemia is greater than it would be with the GLP-1 alone.

Current semaglutide and tirzepatide prescribing information therefore advises clinicians to consider reducing concomitant insulin or insulin-secretagogue doses when appropriate to lower hypoglycemia risk.

That recommendation is directed at treatment management, not self-adjustment. You should not automatically reduce your insulin or sulfonylurea on the day you begin a GLP-1 unless the clinician managing your diabetes has given you that plan.

What the interaction tells you is that your existing diabetes regimen may need to change as glucose control and food intake change.

What Hypoglycemia Can Feel Like

If you use insulin or a sulfonylurea with a GLP-1, know your personal monitoring instructions and hypoglycemia treatment plan. Symptoms can include shakiness, sweating, a rapid heartbeat, hunger, dizziness, weakness, irritability, confusion or difficulty concentrating.

Severe hypoglycemia can progress to loss of consciousness or seizures and requires urgent treatment. The risk deserves particular attention when you have recently increased your GLP-1 dose or when your appetite and food intake have changed dramatically.

The interaction is therefore broader than two medications meeting in the bloodstream. It can involve GLP-1 effect + reduced food intake + an existing insulin or sulfonylurea regimen.

That is why your actual glucose readings and symptoms matter more than the fact that the drug combination appears on a medication list.

Thyroxine Absorption Kinetics and TSH Monitoring

This is another area where the details matter more than a broad statement such as “GLP-1s interfere with thyroid medicine.”

If you take levothyroxine and injectable Ozempic, you may encounter warnings online suggesting that semaglutide automatically changes levothyroxine absorption. The strongest direct pharmacokinetic evidence, however, involves oral semaglutide, not injectable Ozempic.

That distinction makes sense when you consider how the medications are administered. Oral semaglutide and levothyroxine both have unusual absorption requirements, while injectable semaglutide bypasses the gastrointestinal absorption step entirely.

Understanding which formulation was actually studied prevents a real drug interaction from being generalized beyond what the evidence supports.

Oral semaglutide and levothyroxine have competing administration issues

Levothyroxine is highly sensitive to administration conditions. Food, supplements and other medications can interfere with how much of the drug is absorbed.

Oral semaglutide also has very specific fasting and water requirements because its own absorption through the stomach is unusually sensitive to how it is taken. That creates an obvious challenge when two medications both depend on carefully controlled morning administration.

In a pharmacokinetic study in which oral semaglutide and levothyroxine were taken together, total thyroxine exposure increased by approximately 33% compared with levothyroxine alone.

That does not mean everyone who uses both medications will become hyperthyroid. It does mean the interaction is large enough that thyroid-function monitoring should be considered when the medications are used together.

For someone taking both, the answer is not to invent a medication schedule from memory. It is to have a pharmacist or prescriber help build a schedule that preserves the administration requirements of both drugs.

Injectable Ozempic is different

Ozempic is administered subcutaneously, so it does not have to compete with levothyroxine for the same oral absorption conditions.

That means you should not take the 33% increase observed with oral semaglutide and translate it into the claim that Ozempic increases levothyroxine absorption by 33%. That is not what the study showed.

Injectable semaglutide can still be relevant to thyroid replacement for a different reason, however. If GLP-1 treatment leads to substantial weight loss, the levothyroxine dose that once fit your body may eventually need reassessment.

That is not necessarily a direct pharmacokinetic interaction. It is a change in the clinical context surrounding the medication.

Weight Loss Can Change Your Levothyroxine Requirement

Levothyroxine dosing is influenced by multiple factors, including body size. If you lose a substantial amount of weight, the dose that was appropriate before treatment may eventually become more than you need.

That distinction is important because it is not the same as saying semaglutide chemically interferes with levothyroxine. Your body has changed, and your replacement requirement may change with it.

A 2026 study examining thyroid-stimulating hormone testing after GLP-1 receptor agonist initiation in people taking levothyroxine highlighted the importance of reassessing thyroid function in this population. Published cases have also described levothyroxine over-replacement and biochemical hyperthyroidism after substantial weight loss during semaglutide treatment.

If you take levothyroxine and are losing significant weight on a GLP-1, periodic TSH monitoring is therefore reasonable even when your GLP-1 is injectable.

Symptoms such as new palpitations, tremor, heat intolerance, unusual anxiety, unexplained sweating or insomnia should not automatically be attributed to the GLP-1. They may be a reason to reassess whether your thyroid replacement dose still fits your current needs.

What About Other Oral Medications?

GLP-1 and related incretin medications can delay gastric emptying, so their prescribing information generally acknowledges the potential to affect absorption of oral medications.

That does not mean every tablet you take becomes unreliable. For many commonly studied medications, clinically meaningful changes in exposure have not been demonstrated.

The medications that deserve more attention are those in which relatively small changes in drug exposure can matter clinically. These may include drugs with a narrow therapeutic index or medications that need to reach a particular concentration to work reliably.

Current tirzepatide labeling specifically advises monitoring people taking oral medications that depend on threshold concentrations or have a narrow therapeutic index, with warfarin cited as an example.

This is an area where your pharmacist can be especially helpful. You do not need to calculate absorption kinetics for every tablet in your pill organizer; you need someone familiar with your actual medication list to identify the relatively small number for which altered absorption might matter.

That is a much more practical approach than assuming that delayed gastric emptying makes all oral medication unreliable.

Oral GLP-1s Create an Additional Medication-Timing Problem

If your GLP-1 medication is itself a tablet, medication timing becomes more complicated.

Oral semaglutide has specific fasting and water requirements because its absorption is highly sensitive to how it is taken. Taking other tablets during the same administration window can alter semaglutide exposure.

This becomes particularly relevant if another morning medication also has fasting requirements. Levothyroxine is the obvious example, but the broader issue is that two medications may both need access to the same carefully controlled empty-stomach window.

If you take several morning medications, do not simply swallow them all together and assume the timing does not matter. Ask your pharmacist or prescriber to help you create a schedule that preserves the administration requirements of the medications involved.

Sometimes the interaction is not that two drugs are inherently unsafe together. It is that both medications want the same empty stomach at the same time, and the schedule has to account for that.

Dehydration, NSAIDs, and Acute Kidney Injury Factors

This interaction works differently from the contraceptive, insulin or oral-medication examples.

There is not a classic direct interaction in which semaglutide and ibuprofen combine to form a new toxic substance. The concern is the physiological situation that can develop when GLP-1 side effects become significant.

GLP-1 medications can cause nausea, vomiting and diarrhea, and they can sometimes reduce food and fluid intake dramatically. If those symptoms are severe enough, you can become volume depleted, which can reduce blood flow to the kidneys.

Current semaglutide and tirzepatide prescribing information includes warnings about acute kidney injury related to volume depletion, particularly in people experiencing substantial gastrointestinal adverse effects.

Now add an NSAID. Medications such as ibuprofen and naproxen affect prostaglandin pathways that help support blood flow through the kidneys.

In a well-hydrated person with normal kidney function who occasionally uses an NSAID, that may not create a problem. In someone who has been vomiting, barely drinking and is already volume depleted, the same medication is being taken in a very different physiological environment.

NSAIDs Aren't Automatically Forbidden on a GLP-1

This distinction matters because the kidney warning can easily turn into an overly broad rule.

Taking Ozempic, Wegovy, Mounjaro or Zepbound does not automatically mean you can never take ibuprofen or naproxen again. There is no universal GLP-1 rule prohibiting NSAIDs.

The risk becomes more important when several kidney stressors accumulate at the same time. Those can include dehydration, persistent vomiting or diarrhea, chronic kidney disease, older age or frailty, diuretics, ACE inhibitors or ARBs, and NSAID use.

A medication that is usually tolerated well can therefore become more concerning during an acute illness or period of poor intake. The surrounding clinical situation changes the risk.

So the useful question is not simply “Can I take Advil with my GLP-1?” It is “Am I currently dehydrated, acutely ill or otherwise at increased risk for kidney injury?”

That context can change the answer considerably.

The Day You're Sick Matters More Than the Day You're Well

Imagine that you normally take a GLP-1 and occasionally use naproxen for joint pain. You have been stable for months, are eating and drinking normally, and have had no significant gastrointestinal symptoms.

Then you increase your GLP-1 dose and develop persistent vomiting and diarrhea. You are barely keeping fluids down and feel lightheaded when you stand.

Your medication list may look exactly the same on paper, but your physiology has changed.

That is why significant gastrointestinal illness should trigger a broader medication review rather than only a discussion about stopping the nausea. Hydration status, kidney function, glucose-lowering medications, blood-pressure medications, diuretics and other therapies can all become relevant during acute volume depletion.

Do not independently stop essential prescription medications because you found a generic “sick-day list” online. But if vomiting or diarrhea is persistent or you cannot maintain adequate fluid intake, contact your healthcare team so your actual medication regimen can be reviewed in the context of what is happening now.

The day you are sick can create risks that were not present when you were well, even though none of the prescriptions in your medication organizer changed.

What About Acetaminophen?

Acetaminophen is not an NSAID and does not affect kidney blood flow through the same prostaglandin mechanism as ibuprofen or naproxen.

That does not make acetaminophen universally risk-free. Excessive acetaminophen can cause serious liver injury, and appropriate dosing depends on the person, the total daily dose and whether other combination products also contain acetaminophen.

The important distinction is simply that acetaminophen and NSAIDs are not the same medication class and should not be discussed as though they create identical kidney risks during dehydration.

If you need frequent pain medication while taking a GLP-1, that is a better reason to talk with your clinician or pharmacist than to repeatedly alternate between over-the-counter options without considering your kidney function, liver health and other medications.

Other Medications Worth Reviewing

You do not need to fear every medication combination when starting a GLP-1, but several categories deserve deliberate review.

Insulin and insulin secretagogues matter because hypoglycemia risk can increase. Oral hormonal contraceptives with tirzepatide deserve specific attention because temporary additional contraception is recommended after initiation and dose escalation.

Narrow-therapeutic-index or concentration-sensitive oral medications may require monitoring because delayed gastric emptying can affect absorption. Levothyroxine deserves attention particularly with oral semaglutide and during substantial weight loss.

Diuretics, ACE inhibitors, ARBs and NSAIDs are not universally incompatible with GLP-1 treatment, but dehydration can change the kidney-risk picture. Your clinician should also know about any additional diabetes medications and any other product containing a GLP-1 receptor agonist or tirzepatide.

The purpose of this review is not to create an enormous prohibited-medication list. It is to identify the handful of medications whose dose, absorption, monitoring or risk may need to change when your physiology changes.

What About Supplements?

Supplements belong on the same medication list as prescriptions and over-the-counter drugs.

The word natural does not mean pharmacologically irrelevant. Some supplements can influence blood glucose, blood pressure, bleeding risk or gastrointestinal symptoms, while others can interfere with the absorption of medications such as levothyroxine.

That does not mean you need to empty your vitamin cabinet before starting a GLP-1. It means your medication review should include prescriptions, over-the-counter medications, vitamins, minerals, herbal products and other weight-loss products.

This is particularly important if you use supplements marketed for glucose control or weight loss. Combining multiple products that influence the same physiological system can make it harder to determine what is causing a benefit or side effect.

Your pharmacist cannot identify an interaction with something they do not know you are taking, so include supplements when you provide your medication history.

When You Should Contact Your Healthcare Team

Contact your prescriber or pharmacist if you are starting a GLP-1 and you also use insulin, a sulfonylurea, oral hormonal contraception with tirzepatide, levothyroxine or a medication that requires particularly precise blood levels.

You should also seek medical guidance if you develop repeated hypoglycemia, severe or persistent vomiting or diarrhea, inability to maintain adequate fluid intake, markedly decreased urination, dizziness or fainting associated with dehydration, confusion, severe weakness or symptoms suggesting significant thyroid over-replacement while taking levothyroxine.

Severe hypoglycemia, loss of consciousness or another medical emergency requires immediate care. Those situations should not be managed by waiting to see whether the symptoms improve after the next dose is skipped.

For less urgent concerns, your pharmacist is often one of the best people to review the entire medication list because many GLP-1 interactions depend on formulation, timing, dose and route rather than the medication name alone.

What to Do Before Your First Dose

The most useful thing you can bring to a GLP-1 appointment is not a list of every interaction you found online. It is an accurate list of everything you actually take, including the dose, route and frequency.

Then ask three practical questions: Could my GLP-1 change the absorption of any of these medications? Could any of these medications amplify its glucose-lowering effect? If I develop significant vomiting, diarrhea or reduced intake, are there medications on this list that need special instructions?

Those questions get much closer to the interactions that matter in real life because GLP-1 drug interactions are not limited to whether two molecules can technically exist in your body at the same time.

They are also about what happens when your digestion slows, your glucose improves, your appetite changes, your weight falls or you become dehydrated.

Most medications you took safely before starting a GLP-1 will probably remain part of your life afterward. A few may need closer monitoring, some may eventually need dose adjustment by your clinician, and one particularly important interaction — oral hormonal contraception with tirzepatide — may temporarily require additional contraceptive protection.

You do not need to be afraid of your medication list. You need to know where the GLP-1 actually changes the equation.

Sources

1. Eli Lilly and Company. Zepbound (tirzepatide) U.S. Prescribing Information. Revised 2026.
   https://pi.lilly.com/us/zepbound-uspi.pdf
2. Eli Lilly and Company. Mounjaro (tirzepatide) U.S. Prescribing Information.
   https://pi.lilly.com/us/mounjaro-uspi.pdf
3. Novo Nordisk. Ozempic (semaglutide) U.S. Prescribing Information.
   https://www.novo-pi.com/ozempic.pdf
4. Novo Nordisk. Rybelsus (oral semaglutide) U.S. Prescribing Information.
   https://www.novo-pi.com/rybelsus.pdf
5. Hauge C, et al. Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide. Expert Opinion on Drug Metabolism & Toxicology. 2021.
   https://pubmed.ncbi.nlm.nih.gov/34289755/
6. Chen Y, et al. Patterns of TSH test after GLP-1 RAs initiation in patients on levothyroxine: a trial emulation study.Journal of Clinical Endocrinology & Metabolism. 2026.
   https://pubmed.ncbi.nlm.nih.gov/41902399/
7. National Kidney Foundation. Acute Kidney Injury (AKI): Causes, Symptoms, and Treatment.
   https://www.kidney.org/kidney-topics/acute-kidney-injury-aki
8. National Kidney Foundation. Medication Dosing and Kidney Disease. Updated June 26, 2026.
   https://www.kidney.org/kidney-topics/medication-dosing-and-kidney-disease